Page last updated: 2024-11-12
alisol a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
alisol A: has anti-hepatitis B virus activity; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 15558616 |
| CHEMBL ID | 467814 |
| MeSH ID | M0040055 |
Synonyms (20)
| Synonym |
|---|
| (5r,8s,9s,10s,11s,14r)-11-hydroxy-4,4,8,10,14-pentamethyl-17-[(1r,3s,4r)-3,4,5-trihydroxy-1,5-dimethyl-hexyl]-1,2,5,6,7,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-3-one |
| bdbm50130907 |
| 19885-10-0 |
| alisol a |
| CHEMBL467814 |
| dammar-13(17)-en-3-one, 11,23,24,25-tetrahydroxy-, (8alpha,9beta,11beta,14beta,23s,24r)- |
| S9277 |
| CS-3647 |
| AC-35101 |
| alisol-a |
| HY-N0853 |
| AKOS037514543 |
| BS-15882 |
| mfcd09953906 |
| 11,23,24,25-tetrahydroxydammar-13(17)-en-3-one |
| DTXSID10941738 |
| Q63408699 |
| CCG-269618 |
| (5r,8s,9s,10s,11s,14r)-11-hydroxy-4,4,8,10,14-pentamethyl-17-[(2r,4s,5r)-4,5,6-trihydroxy-6-methylheptan-2-yl]-1,2,5,6,7,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-3-one |
| alisola |
Research Excerpts
Overview
Alisol A is a bioactive triterpenoid isolated from the Rhizoma Alismatis.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Alisol A is a bioactive triterpenoid isolated from the Rhizoma Alismatis. " | ( Alisol A Inhibited the Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma Cells by Inhibiting the Hippo Signaling Pathway. Chen, X; Liu, H, 2021) | 3.51 |
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Alisol A treatment can induce autophagy‑dependent apoptosis in human breast cancer cells via induction of ROS and DNA damage." | ( Alisol A is potentially therapeutic in human breast cancer cells. Li, M; Shi, L; Shi, Y; Wang, H; Wang, M; Wang, P; Yu, J; Zhang, Q; Zhang, T; Zhao, H, 2020) | 2.72 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (2)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cocaine esterase | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0058 | 2.4330 | 6.8000 | AID1255832 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Activation Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Bile acid receptor | Homo sapiens (human) | EC50 (µMol) | 10.1600 | 0.0040 | 1.4191 | 10.0000 | AID1609537 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (51)
Molecular Functions (18)
Ceullar Components (9)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| endoplasmic reticulum | Cocaine esterase | Homo sapiens (human) |
| endoplasmic reticulum lumen | Cocaine esterase | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Cocaine esterase | Homo sapiens (human) |
| nucleoplasm | Bile acid receptor | Homo sapiens (human) |
| chromatin | Bile acid receptor | Homo sapiens (human) |
| euchromatin | Bile acid receptor | Homo sapiens (human) |
| receptor complex | Bile acid receptor | Homo sapiens (human) |
| RNA polymerase II transcription regulator complex | Bile acid receptor | Homo sapiens (human) |
| nucleus | Bile acid receptor | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (8)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID361554 | Cytotoxicity against human HepG2.2.15 cells | 2008 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16 | Anti-HBV agents. Part 1: Synthesis of alisol A derivatives: a new class of hepatitis B virus inhibitors. |
| AID1255833 | Inhibition of human carboxylesterase 1 using 2-(2'-benzoyl-3'-methoxylphenyl)-benzothiazole as substrate at 0.1 to 200 uM by fluorescence assay | 2015 | Journal of natural products, Oct-23, Volume: 78, Issue:10 | Protostane Triterpenoids from the Rhizome of Alisma orientale Exhibit Inhibitory Effects on Human Carboxylesterase 2. |
| AID361555 | Antiviral activity against hepatitis B virus-infected human HepG2.2.15 cells assessed as inhibition of HBV e antigen secretion | 2008 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16 | Anti-HBV agents. Part 1: Synthesis of alisol A derivatives: a new class of hepatitis B virus inhibitors. |
| AID361558 | Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for HBV surface antigen secretion | 2008 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16 | Anti-HBV agents. Part 1: Synthesis of alisol A derivatives: a new class of hepatitis B virus inhibitors. |
| AID1609537 | Transactivation of FXR (unknown origin) transfected in HepG2 cells co-expressing pBSEP/pGL4.74 incubated for 24 hrs by luciferase reporter gene assay | 2019 | European journal of medicinal chemistry, Nov-15, Volume: 182 | Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism. |
| AID1255832 | Inhibition of human carboxylesterase 2 using 4-benzoyl-N-butyl-1,8-naphthalimide as substrate by fluorescence assay | 2015 | Journal of natural products, Oct-23, Volume: 78, Issue:10 | Protostane Triterpenoids from the Rhizome of Alisma orientale Exhibit Inhibitory Effects on Human Carboxylesterase 2. |
| AID361556 | Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for HBV e antigen secretion | 2008 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16 | Anti-HBV agents. Part 1: Synthesis of alisol A derivatives: a new class of hepatitis B virus inhibitors. |
| AID361557 | Antiviral activity against hepatitis B virus-infected human HepG2.2.15 cells assessed as inhibition of HBV surface antigen secretion | 2008 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16 | Anti-HBV agents. Part 1: Synthesis of alisol A derivatives: a new class of hepatitis B virus inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (24)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 5 (20.83) | 29.6817 |
| 2010's | 15 (62.50) | 24.3611 |
| 2020's | 3 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 22.70
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.70) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 24 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||